VOLUME 63   2002   SUPPLEMENT 9

ARTICLES

3 Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment. Herbert Y. Meltzer
[PDF]

5 Risk of Cardiovascular Disease and Sudden Death in Schizophrenia. Michael Davidson
[Abstract] [PDF]

12 Clinical Management of Cardiovascular Risks During Treatment With Psychotropic Drugs. Alexander H. Glassman
[Abstract] [PDF]

18 Mechanisms and Risks of Electrocardiographic QT Interval Prolongation When Using Antipsychotic Drugs. W. Victor R. Vieweg
[Abstract] [PDF]

25 Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment. Herbert Y. Meltzer, Michael Davidson, Alexander H. Glassman, and W. Victor R. Vieweg
[Abstract] [PDF]

CME SECTION

30 Instructions and Posttest.
[PDF]

32 Registration Form and Evaluation.
[PDF]